A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Conditions

Diseases of the Nervous System

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to assess the efficacy, safety, and tolerability profile of CVL-865 as adjunctive treatment in participants with drug-resistant focal onset seizures.

Ages
18 years - 75 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Cerevel Therapeutics, LLC
Start Date
07/25/2020
End Date
10/31/2022

For more information about this study, contact:

Daniel Doherty

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Hamada Hamid Altalib, DO, MPH, FAES
Associate Professor of Neurology and of Psychiatry; Track Director, Health Informatics, Online Executive MPH Program

Sub-Investigator

Lawrence Hirsch, MD

Last Updated
06/19/2022
Study HIC
#2000027109

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigator

Contact Information